EVOK vs AYTU vs SUPN vs PRGO vs NKTR

For growth investors, Evoke Pharma, Inc.

(EVOK) is the stronger pick with 97. 8% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Analysts rate Supernus Pharmaceuticals, Inc. (SUPN) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Supernus Pharmaceuticals, Inc.

(SUPN) delivered a total return of +78. 0%, compared to -97. 8% for Aytu BioPharma, Inc. (AYTU). Over 10 years, the gap is even starker: SUPN returned +223. 7% versus AYTU's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Evoke Pharma, Inc.

(EVOK) is the lower-risk stock at -0. 17β versus Nektar Therapeutics's 1. 80β — meaning NKTR is approximately -1172% more volatile than EVOK relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Evoke Pharma, Inc.

(EVOK) is pulling ahead at 97. 8% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Evoke Pharma, Inc. grew EPS 90. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, EVOK leads at 85. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Supernus Pharmaceuticals, Inc.

(SUPN) is the more profitable company, earning -5. 4% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps -5. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 20. 8x for Supernus Pharmaceuticals, Inc. — 15. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 208. 9% to $36. 20.

In this comparison, PRGO (9.

8% yield) pays a dividend. EVOK, AYTU, SUPN, NKTR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Evoke Pharma, Inc.

(EVOK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 17)). Nektar Therapeutics (NKTR) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EVOK: -98. 5%, NKTR: -59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EVOK is a small-cap high-growth stock; AYTU is a small-cap quality compounder stock; SUPN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; NKTR is a small-cap quality compounder stock. PRGO pays a dividend while EVOK, AYTU, SUPN, NKTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.